Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists

References

• Mosca L, Jones W K, King K B, Ouyang P, Redberg R F, Hill M N. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women's Heart Disease and Stroke Campaign Task Force. Arch Fam Med 2000; 9: 506–515
   PubMedGoogle Scholar
• Weisz D, Gusmano M K, Rodwin V G. Gender and the treatment of heart disease in older persons in the United States, France, and England: a comparative, population-based view of a clinical phenomenon. Gend Med 2004; 1: 29–40
   PubMedGoogle Scholar
• Peterson S, Peto V, Rayner M, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics2nd edn. British Heart Foundation, London 2005
   Google Scholar
• Stramba-Badiale M, Fox K M, Priori S G, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27: 994–1005
   PubMed Web of Science ®Google Scholar
• Benagiano G, Farris M. Why a consensus conference on hormone replacement therapy and the cardiovascular system?. Maturitas 2004; 47: 245–253
   PubMed Web of Science ®Google Scholar
• Naftolin F, Schneider H P, Sturdee D W, , Executive Committee of the International Menopause Society, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333–337
   PubMed Web of Science ®Google Scholar
• Ouyang P, Michos E D, Karas R H. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47: 1741–1753
   PubMed Web of Science ®Google Scholar
• Unal B, Critchley J A, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101–1107
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547–1557
   PubMed Web of Science ®Google Scholar
• Simon T, Mary-Krause M, Cambou J P, , USIC Investigators, et al. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women: results from the French nation-wide USIC registries. Eur Heart J 2006; 27: 1282–1288
   PubMed Web of Science ®Google Scholar
• Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103: 375–380
   PubMed Web of Science ®Google Scholar
• Reunanen A, Suhonen O, Aromaa A, Knekt P, Pyorala K. Incidence of different manifestations of coronary heart disease in middle-aged Finnish men and women. Acta Med Scand 1985; 218: 19–26
   PubMed Web of Science ®Google Scholar
• Lerner D J, Kannel W B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383–390
   PubMed Web of Science ®Google Scholar
• Bugiardini R, Bairey Merz C N. Angina with “normal” coronary arteries: a changing philosophy. JAMA 2005; 293: 477–484
   PubMed Web of Science ®Google Scholar
• Senoz S, Direm B, Gulekli B, Gokmen O. Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women. Maturitas 1996; 25: 107–114
   PubMed Web of Science ®Google Scholar
• Kearney P M, Whelton M, Reynolds K, Muntner P, Whelton P K, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913
   PubMed Web of Science ®Google Scholar
• Women and smoking: a report of the Surgeon General. Executive summary. MMWR Recomm Rep 2002; 51: i–iv
   PubMedGoogle Scholar
• Prescott E, Hippe M, Schnohr P, Hein H O, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–1047
   PubMed Web of Science ®Google Scholar
• Castelli W P. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol 1999; 180: S349–356
   PubMed Web of Science ®Google Scholar
• Goldbaum G M, Kendrick J S, Hogelin G C, Gentry E M. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987; 258: 1339–1342
   PubMed Web of Science ®Google Scholar
• Rangemark C, Benthin G, Granstrom E F, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992; 86: 1495–1500
   PubMed Web of Science ®Google Scholar
• Dotevall A, Rangeark C, Erikssib E, Kutti J, Wadenvik H, Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost 1992; 68: 583–588
   PubMed Web of Science ®Google Scholar
• Kalra V K, Ying Y, Deemer K, Natarajan R, Nadler J L, Coates T D. Mechanism of cigarette smoke condensate induced adhesion of human monocytes in cultured endothelial cells. J Cell Physiol 1994; 160: 154–162
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994; 49: 579–592
   PubMed Web of Science ®Google Scholar
• WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202–1209
   PubMed Web of Science ®Google Scholar
• Keeling D. Combined oral contraceptives and the risk of myocardial infarction. Ann Med 2003; 35: 413–418
   PubMed Web of Science ®Google Scholar
• Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives, an updated analysis of a cohort study. Br J Obstet Gynaecol 1998; 105: 890–896
   PubMedGoogle Scholar
• Jonsdottir L S, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002; 9: 67–76
   PubMedGoogle Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, , Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610
   PubMed Web of Science ®Google Scholar
• Barter P, Kastelein J, Nunn A, Hobbs R, Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168: 195–211
   PubMed Web of Science ®Google Scholar
• Forouhi N G, Merrick D, Goyder E, et al. Diabetes prevalence in England, 2001 – estimates from an epidemiological model. Diabet Med 2006; 23: 189–197
   PubMed Web of Science ®Google Scholar
• Ding E L, Song Y, Malik V S, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288–1299
   PubMed Web of Science ®Google Scholar
• Lobner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006; 55: 792–797
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention of diabetes. Report of the WHO study group. Technical series 844. 2004. WHO, Geneva
   Google Scholar
• DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003; 26: 688–696
   PubMed Web of Science ®Google Scholar
• Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect of gender on outcomes of acute coronary syndromes. Am J Cardiol 2003; 91: 1466–1469
   PubMed Web of Science ®Google Scholar
• EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001
   PubMed Web of Science ®Google Scholar
• Kanaya A M, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002; 162: 1737–1745
   PubMed Web of Science ®Google Scholar
• Sprafka J M, Burke G L, Folsom A R, McGovern P G, Hahn L P. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care 1991; 14: 537–543
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73–78
   PubMed Web of Science ®Google Scholar
• Pyorala K, Lehto S, De Bacquer D, , EUROASPIRE I Group; EUROASPIRE II Group, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47: 1257–1265
   PubMed Web of Science ®Google Scholar
• Guthrie J R, Dennerstein L, Taffe J R, Lehert P, Burger H G. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 2004; 7: 375–389
   PubMed Web of Science ®Google Scholar
• Hu F B, Willett W C, Li T, Stampfer M J, Colditz G A, Manson J E. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351: 2694–2703
   PubMed Web of Science ®Google Scholar
• Alberti K G, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480
   PubMed Web of Science ®Google Scholar
• Grundy S M, Brewer H B, Jr, Cleeman J I, Smith S C, Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143–3421
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19(Suppl A)A2–11
   PubMedGoogle Scholar
• Kaaja R J, Poyhonen-Alho M K. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006; 24: 131–141
   PubMed Web of Science ®Google Scholar
• Kaaja R, Laivuori H, Pulkki P, Tikkanen M J, Hiilesmaa V, Ylikorkala O. Is there any link between insulin resistance and inflammation in established preeclampsia?. Metabolism 2004; 53: 1433–1435
   PubMed Web of Science ®Google Scholar
• Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol 2004; 93: 805–808
   PubMed Web of Science ®Google Scholar
• Bernstein M S, Morabia A, Sloutkis D. Definition and prevalence of sedentarism in an urban population. Am J Public Health 1999; 89: 862–867
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Blumel J E, Roncagliolo M E, et al. Age, menopause and hormone replacement therapy influences on cardiovascular risk factors in a cohort of middle-aged Chilean women. Maturitas 2003; 45: 205–212
   PubMed Web of Science ®Google Scholar
• Lukkarinen H, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among women with coronary heart disease. Heart Lung 1998; 27: 189–199
   PubMed Web of Science ®Google Scholar
• Barford A, Dorling D, Davey-Smith G, Shaw M. Life expectancy: women now on top everywhere. BMJ 2006; 332: 808
   PubMed Web of Science ®Google Scholar
• United Nations. Population aging, www.un.org/esa/population/publications/aging99 (1999)
   Google Scholar
• Anderson G D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005; 14: 19–29
   PubMed Web of Science ®Google Scholar
• Burger H G, Dudley E C, Robertson D M, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002; 57: 257–5
   PubMedGoogle Scholar
• Buckler H. The menopause transition: endocrine changes and clinical symptoms. J Br Menopause Soc 2005; 11: 61–65
   PubMedGoogle Scholar
• Zichella L. Clinical management of the menopausal woman. Int J Fertil Menopausal Stud 1993; 38(Suppl 1)15–22
   PubMedGoogle Scholar
• Baum L W. Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2005; 60: 736–743
   PubMed Web of Science ®Google Scholar
• Oldenhave A, Jaszmann L J, Haspels A A, Everaerd W T. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993; 168: 772–780
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Hot flushes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994; 29: 319–336
   PubMed Web of Science ®Google Scholar
• Barnabei V M, Grady D, Stovall D W, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002; 100: 1209–1218
   PubMed Web of Science ®Google Scholar
• Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7: 189–196
   PubMed Web of Science ®Google Scholar
• Nelson H D, Vesco K K, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057–2071
   PubMed Web of Science ®Google Scholar
• Vanwesenbeeck I, Vennix P, van de Wiel H. ‘Menopausal symptoms’: associations with menopausal status and psychosocial factors. J Psychosom Obstet Gynaecol 2001; 22: 149–158
   PubMed Web of Science ®Google Scholar
• Derman R J, Dawood M Y, Stone S. Quality of life during sequential hormone replacement therapy – a placebo-controlled study. Int J Fertil Menopausal Stud 1995; 40: 73–78
   PubMed Web of Science ®Google Scholar
• Col N F, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004; 164: 1634–1640
   PubMed Web of Science ®Google Scholar
• Badia X, Diez-Perez A, Lahoz R, Lizan L, Nogues X, Iborra J. The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2004; 2: 41
   PubMedGoogle Scholar
• Rossouw J E, Anderson G L, Prentice R L, , Writing Group for the Women's Health Initiative Investigators, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Kannel W B, Hjortland M C, McNamara P M, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85: 447–452
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani A R. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001; 39: 125–132
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 1995; 44: 15–17
   PubMed Web of Science ®Google Scholar
• Matthews K A, Meilahn E, Kuller L H, Kelsey S F, Caggiula A W, Wing R R. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 698–699
   Google Scholar
• Staessen J A, Li Y, Thijs L, Wang J G. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005; 28: 385–407
   PubMed Web of Science ®Google Scholar
• Lindheim S R, Buchanan T A, Duffy D M, et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1994; 1: 150–154
   PubMedGoogle Scholar
• Samsioe G. HRT and cardiovascular disease. Ann N Y Aad Sci 2003; 997: 358–372
   PubMed Web of Science ®Google Scholar
• Eilertsen A L, Hoibraaten E, Os I, Andersen T O, Sándwich L, Sandset P M. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005; 52: 111–118
   PubMed Web of Science ®Google Scholar
• Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243–3253
   PubMed Web of Science ®Google Scholar
• Kuhl H. Breast cancer risk in the WHI study: the problem of obesity. Maturitas 2005; 51: 83–97
   PubMed Web of Science ®Google Scholar
• Stefanick M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
   PubMed Web of Science ®Google Scholar
• Chen W Y, Manson J E, Hankinson S E, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166: 1027–1032
   PubMed Web of Science ®Google Scholar
• Sullivan J M, El Zeky F, Vander Z R, Ramanathan K B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79: 847–850
   PubMed Web of Science ®Google Scholar
• Shlipak M G, Angeja B G, Go A S, Frederick P D, Canto J G, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001; 104: 2300–2304
   PubMed Web of Science ®Google Scholar
• Dias A R, Jr, Melo R N, Gebara O C, et al. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 2005; 8: 63–70
   PubMed Web of Science ®Google Scholar
• Clarkson T B. Progestogens and cardiovascular disease. A critical review. J Reprod Med 1999; 44: 180–184
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, , Women's Health Initiative Investigators, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, , Women's Health Initiative Investigators, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, , Women's Health Initiative Investigators, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006; 15: 35–44
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller L H, Prentice R, , Women's Health Initiative Investigators, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–1580
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix S L, Limacher M, , WHI Investigators, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673–2684
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Prentice R L, Manson J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Bartys S, Baker D, Lewis P, Middleton E. Inequity in recording of risk in a local population-based screening programme for cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 63–67
   PubMed Web of Science ®Google Scholar
• O'Brien E, Asmar R, Beilin L, , European Society of Hypertension Working Group on Blood Pressure Monitoring, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697–701
   PubMed Web of Science ®Google Scholar
• Conroy R M, Pyorala K, Fitzgerald A P, , SCORE project group, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003
   PubMed Web of Science ®Google Scholar
• Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003; 327: 1264–1268
   PubMed Web of Science ®Google Scholar
• McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognositic significance of stable angina pectoris among woman and men. JAMA 2006; 295: 1404–1411
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J.Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• Hersberger M, von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb Exp Pharmacol 2005; 170: 537–561
   PubMedGoogle Scholar
• Marshall T. Coronary heart disease prevention: insights from modeling incremental cost effectiveness. BMJ 2003; 327: 1264
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen T A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206
   PubMed Web of Science ®Google Scholar
• Messerli F, White W B, Staessen J A. If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 2002; 40: 2201–2203
   PubMed Web of Science ®Google Scholar
• Coleman A J, Steel S D, Ashworth M, Vowler S L, Shennan A. Accuracy of the pressure scale of sphygmomanometers in clinical use within primary care. Blood Press Monit 2005; 10: 181–188
   PubMed Web of Science ®Google Scholar
• MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994; 12(Suppl)S5–14
   Google Scholar
• Vasan R S, Larson M G, Leip E P, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297
   PubMed Web of Science ®Google Scholar
• Svetkey L P. Management of prehypertension. Hypertension 2005; 45: 1056–1061
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt S D, Egan B M, , Trial of Preventing Hypertension (TROPHY) Study Investigators, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697
   PubMed Web of Science ®Google Scholar
• Reckelhoff J F, Fortepiani L A. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43: 918–923
   PubMed Web of Science ®Google Scholar
• Kass D A. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 2005; 46: 185–193
   PubMed Web of Science ®Google Scholar
• Hall J E, Guyton A C, Coleman T G, Mizelle H L, Woods L L. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc 1986; 45: 2897–2903
   PubMedGoogle Scholar
• Basso N, Paglia N, Stella I, et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128: 247–252
   PubMed Web of Science ®Google Scholar
• Duprez D, De Buyzere M, Rietzschel E R, Clement D L. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327–334
   PubMedGoogle Scholar
• Struthers A D, MacDonald T M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663–670
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Preston R A, Alonso A, Panzitta D, Zhang P, Karara A H. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15: 816–822
   PubMed Web of Science ®Google Scholar
• Preston R A, White W B, Pitt B, Bakris G, Norris P M, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804
   PubMed Web of Science ®Google Scholar
• White W B, Pitt B, Preston R A, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112: 1979–1984
   PubMed Web of Science ®Google Scholar
• Archer D F, Thorneycroft I H, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–727
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004; 49: 189–203
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever P S, Poulter N R, , ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906
   PubMed Web of Science ®Google Scholar
• Holcomb S S. Selection of antihypertensive agents in patients with risk for diabetes. Curr Hypertens Rep 2005; 7: 461–465
   PubMed Web of Science ®Google Scholar
• Reckelhoff J F, Fortepiani L A. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43: 918–923
   PubMed Web of Science ®Google Scholar
• Ibrahim M M. RAS inhibition in hypertension. J Hum Hypertens 2006; 20: 101–108
   PubMed Web of Science ®Google Scholar
• Lee Y J, Chiang Y F, Tsai J C. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor. Diabetes Care 2000; 23: 427–428
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: 725–741
   PubMed Web of Science ®Google Scholar
• Daly C, Clemens F, Lopez Sendon J L, , Euro Heart Survey Investigators, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113: 490–498
   PubMed Web of Science ®Google Scholar
• Hayward C S, Kelly R P, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 2000; 46: 28–49
   PubMed Web of Science ®Google Scholar
• Stramba-Badiale M, Priori S G. Gender-specific prescription for cardiovascular diseases?. Eur Heart J 2005; 26: 1571–1572
   PubMed Web of Science ®Google Scholar
• Rathore S S, Wang Y, Krumholz H M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403–1411
   PubMed Web of Science ®Google Scholar
• Berger J S, Roncaglioni M C, Avanzini F, Pangrazzi I, Tognoni G, Brown D L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306–313
   PubMed Web of Science ®Google Scholar